Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups
Primary Purpose
Arthropathy of Hip
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
BoneMaster coated acetabular shell.
Plasma Coated Acetabular Shell
Sponsored by
About this trial
This is an interventional treatment trial for Arthropathy of Hip focused on measuring BoneMaster, Total Hip Replacement, Bone Density, Patients suitable for Total Hip Replacement
Eligibility Criteria
Inclusion Criteria
- Patients suitable for THR surgery with a diagnosis of Osteoarthritis
- Patients aged 40 -85 years old.
- Patients with limited co-morbidity - ASA I - III (low risk for surgery)
- Patients must be able to understand instructions and be willing to return for follow up
Exclusion Criteria
- Rheumatoid arthritis
- Patients requiring supplemental screw fixation
- Previous hip surgery to the affected hip
- Patients with significant co-morbidity - ASA IV - V (high risk for surgery)
- Dementia
- Neurological conditions affecting everyday functional ability and hip movement
- The patient is unable to give informed consent
- Patients who have suffered from cancer
- The patient is currently part of another research study
- Patients who need to take Non Steroidal Anti-inflammatory Drugs (NSAIDs) in the first 6 weeks after surgery
Sites / Locations
- William Harvey Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Plasma-sprayed shell
BoneMaster coated shell
Arm Description
Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
Outcomes
Primary Outcome Measures
Record and Measure Bone Density Using DEXA Scans at 24 Months.
DEXA scan cohort - DEXA scan was used to measure bone density. Below is the calculated net average bone mineral density (BMD) percentage change from baseline at 2 years.
Radiography to Determine Radiolucency in All Three DeLee & Charnley Zones of the Acetabulum.
34 patient cases without duplicated data were the basis for the radiographic analysis that was conducted: Bonemaster group, n = 12; Plasma-Sprayed group, n = 22. The degree of osseous-fixation was determined by grading: 1-2 mm radiolucencies, classed as not fixated; >2mm radiolucencies, classed as unstable.
Secondary Outcome Measures
Secondary Outcomes Are Functional Assessment Using Harris Hip Score
Modified Harris Hip Score, total score 0-100. A score of <70 is poor, 70-79 is fair, 80-89 is good, 90-100 is excellent.
Secondary Outcomes Are Clinical Assessment Using Oxford Hip Score
Oxford Hip Score, scored 12-60. The Oxford hip score - this score was based on the original publication where each answer gives a score of 1-5. A score of 1 for each question, represented best outcome/least symptoms. Therefore a total score of 12 was the best overall outcome.
Secondary Outcomes Are Clinical Assessment Using WOMAC Hip Score
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Hip Score, Each question is scored on a scale of 0 (best health state) to 4 (worst health state); total WOMAC hip score, 0 being the best and 96 being the worst.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00859976
Brief Title
Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups
Official Title
Prospective Randomised Control Trial to Compare the Effect Upon Bone Density and Clinical Outcomes When Using BoneMaster HA Coated Acetabular Cups Compared With Plasma Sprayed HA Coated Cups in Patients With Total Hip Replacements
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
May 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zimmer Biomet
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The randomised controlled trial will be carried out on patients that require a total hip replacement (THR) to reduce pain and restore their function. One way of fixing the hip joint to the bone is by coating the implant to encourage the body to grow bone onto the replacement hip. This study is aiming to find out whether the new (Bonemaster) coating allows increased bony growth onto the cup when compared to the usual (plasma-sprayed) coating. This may reduce the incidence of early failures due to poor bony attachment, which is a well known complication for early failure of total hip replacements.
The study will compare two different types of coating (BoneMaster and Plasma-sprayed) on the cup of the replacement hip. Density of the bone immediately surrounding the cup will be observed to see if there are differences between the two groups. The density of bone will be measured using standard x-ray assessment and in a smaller sample of 14 patients, using a special scan called Dual Energy X-ray Absorptiometry (DEXA Scan). Functional comparisons will be assessed through clinical scores.
Detailed Description
The patients will be identified by the orthopaedic surgeon in the orthopaedic clinic and deemed suitable for the study if all inclusion and exclusion criteria are met. 210 patients will be recruited to the study and each patient will be randomised into either of the groups allowing 105 patients into each group. Patients will be followed up at 6 months, 1 year and 2 years after the surgery. All patients will have radiographic assessments at these follow-up intervals, as well as Harris Hip, Oxford Hip and Womac scores. This will allow comparison of the two groups.
The BoneMaster coating has been extensively tested in cell and animal studies and has been evaluated in one previous clinical study and showed favorable results. Further investigation is required to ensure the new coating may enhance bony growth allowing better fixation of the hips in the early period after the operation and also over a longer period of time. The growth needs to be measured using a more sensitive scan than radiographic assessment alone, called DEXA which was also used in the previous study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Arthropathy of Hip
Keywords
BoneMaster, Total Hip Replacement, Bone Density, Patients suitable for Total Hip Replacement
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
167 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Plasma-sprayed shell
Arm Type
Active Comparator
Arm Description
Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Arm Title
BoneMaster coated shell
Arm Type
Experimental
Arm Description
Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
Intervention Type
Device
Intervention Name(s)
BoneMaster coated acetabular shell.
Other Intervention Name(s)
Bonemaster coated Exceed Acetabular Shell
Intervention Description
Bonemaster coated Exceed Acetabular Shell
Intervention Type
Device
Intervention Name(s)
Plasma Coated Acetabular Shell
Other Intervention Name(s)
Plasma Hydroxyapatite coated Exceed Acetabular Shell
Intervention Description
Plasma HA coated Exceed Acetabular Shell
Primary Outcome Measure Information:
Title
Record and Measure Bone Density Using DEXA Scans at 24 Months.
Description
DEXA scan cohort - DEXA scan was used to measure bone density. Below is the calculated net average bone mineral density (BMD) percentage change from baseline at 2 years.
Time Frame
2 years.
Title
Radiography to Determine Radiolucency in All Three DeLee & Charnley Zones of the Acetabulum.
Description
34 patient cases without duplicated data were the basis for the radiographic analysis that was conducted: Bonemaster group, n = 12; Plasma-Sprayed group, n = 22. The degree of osseous-fixation was determined by grading: 1-2 mm radiolucencies, classed as not fixated; >2mm radiolucencies, classed as unstable.
Time Frame
2 years.
Secondary Outcome Measure Information:
Title
Secondary Outcomes Are Functional Assessment Using Harris Hip Score
Description
Modified Harris Hip Score, total score 0-100. A score of <70 is poor, 70-79 is fair, 80-89 is good, 90-100 is excellent.
Time Frame
2 years
Title
Secondary Outcomes Are Clinical Assessment Using Oxford Hip Score
Description
Oxford Hip Score, scored 12-60. The Oxford hip score - this score was based on the original publication where each answer gives a score of 1-5. A score of 1 for each question, represented best outcome/least symptoms. Therefore a total score of 12 was the best overall outcome.
Time Frame
2 years.
Title
Secondary Outcomes Are Clinical Assessment Using WOMAC Hip Score
Description
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Hip Score, Each question is scored on a scale of 0 (best health state) to 4 (worst health state); total WOMAC hip score, 0 being the best and 96 being the worst.
Time Frame
2 years
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
Patients suitable for THR surgery with a diagnosis of Osteoarthritis
Patients aged 40 -85 years old.
Patients with limited co-morbidity - ASA I - III (low risk for surgery)
Patients must be able to understand instructions and be willing to return for follow up
Exclusion Criteria
Rheumatoid arthritis
Patients requiring supplemental screw fixation
Previous hip surgery to the affected hip
Patients with significant co-morbidity - ASA IV - V (high risk for surgery)
Dementia
Neurological conditions affecting everyday functional ability and hip movement
The patient is unable to give informed consent
Patients who have suffered from cancer
The patient is currently part of another research study
Patients who need to take Non Steroidal Anti-inflammatory Drugs (NSAIDs) in the first 6 weeks after surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helmut ZAHN
Organizational Affiliation
William Harvey Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
William Harvey Hospital
City
Ashford
State/Province
Kent
ZIP/Postal Code
TN24 0LZ
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups
We'll reach out to this number within 24 hrs